VIVE - Viveve Medical, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.17
-1.39 (-18.39%)
At close: 4:00PM EDT

6.30 +0.13 (2.11%)
After hours: 7:32PM EDT

Stock chart is not supported by your current browser
Previous Close7.56
Open7.44
Bid6.30 x 2200
Ask6.18 x 1000
Day's Range5.74 - 7.44
52 Week Range5.74 - 371.00
Volume473,107
Avg. Volume56,000
Market Cap3.588M
Beta (3Y Monthly)-0.01
PE Ratio (TTM)N/A
EPS (TTM)-113.93
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
Trade prices are not sourced from all markets
  • ACCESSWIRE

    Viveve Submits Investigational Testing Application to Conduct Short-Term Feasibility Study in Stress Urinary Incontinence

    ENGLEWOOD, CO / ACCESSWIRE / September 19, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that it has submitted an Investigational Testing Application (ITA) to the Canadian Ministry of Health to conduct a three-arm, three-month feasibility study to compare Viveve's cryogen-cooled monopolar radiofrequency (CMRF) treatment to cryogen-only treatment and to inert sham treatment for the improvement of stress urinary incontinence (SUI) in women. "We are pleased to announce that we have identified a strategic pathway to continue the advancement of our SUI clinical development program and pursuit of a label expansion for this indication on a global basis.

  • ACCESSWIRE

    Viveve and its New CEO are Pioneering Women's Intimate Health

    ENGLEWOOD, CO / ACCESSWIRE / September 18, 2019 / CEOCFO Magazine, an independent investment, healthcare, and medical news publication highlights an executive change at Viveve (VIVE) in an interview (https://www.ceocfointerviews.com/interviews/Viveve19.htm) with CEO and Director, Scott Durbin. States Mr. Durbin, "As a part of the executive leadership team, beginning as CFO in 2013, I have been integral to the company's growth strategy and commercialization efforts. Viveve is at the forefront of the booming demand for clinically proven women's intimate health and wellness treatments.

  • ACCESSWIRE

    Viveve Announces Reverse Stock Split to Regain NASDAQ Compliance

    ENGLEWOOD, CO / ACCESSWIRE / September 18, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that its Board of Directors has approved a one-for-100 reverse stock split of its common stock that is scheduled to become effective after trading closes on September 18, 2019. The company's common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis when the market opens on September 19, 2019. The company's common stock will continue to trade under the symbol "VIVE." At the company's Special Meeting of Stockholders held on September 16, 2019, the company's stockholders approved a proposal authorizing the company's Board of Directors to effect a reverse stock split in a range of 1:20 to 1:100 to help regain compliance with the Nasdaq minimum bid price requirement.

  • ACCESSWIRE

    Viveve to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    ENGLEWOOD, CO / ACCESSWIRE / September 17, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Ladenburg Thalmann 2019 Healthcare Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • Thomson Reuters StreetEvents

    Edited Transcript of VIVE earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 Viveve Medical Inc Earnings Call

  • ACCESSWIRE

    Viveve to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    ENGLEWOOD, CO / ACCESSWIRE / September 3, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the H.C. Wainwright 21st Annual Global Investment Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • ACCESSWIRE

    Viveve Signs Exclusive Distribution Partnership with Paragon Meditech in Hong Kong, China and Macau

    ENGLEWOOD, CO / ACCESSWIRE / September 3, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced an exclusive partnership agreement with Paragon Meditech Co, Ltd., a leading women’s health and medical technology distributor throughout mainland China, Hong Kong and Macau. “We are excited to partner with Paragon Meditech as we continue to expand commercial availability of the Viveve® System worldwide.

  • ACCESSWIRE

    Viveve Signs Exclusive Distribution Partnership in Canada with Salient Medical Solutions

    ENGLEWOOD, CO / ACCESSWIRE / August 22, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today announced an exclusive distribution agreement with Salient Medical Solutions, a leading distributor of innovative world-class medical devices and technologies in Canada. “We are pleased to partner with Salient Medical to expand the commercial availability of the Viveve® System to physicians and healthcare providers throughout Canada,” said Scott Durbin, chief executive officer of Viveve.

  • ACCESSWIRE

    Viveve Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    Company completed successful transition from capital sales to recurring revenue model Achieved U.S. FDA 510k and CE Mark clearances for Viveve 2.0 Expanded international distribution partnership in Middle ...

  • ACCESSWIRE

    Viveve Reports Additional Clinical Results of LIBERATE-International Trial for Stress Urinary Incontinence

    ENGLEWOOD, CO / ACCESSWIRE / August 7, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women’s intimate health, today reported additional clinical results from the LIBERATE-International ...

  • ACCESSWIRE

    Viveve to Host Conference Call to Provide Corporate Update and Second Quarter 2019 Results on August 8, 2019

    ENGLEWOOD, CO / ACCESSWIRE / August 1, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today announced that it will report its second quarter 2019 financial results after the close of the U.S. financial markets on Thursday, August 8, 2019, and will host a live conference call and webcast to provide a corporate update at 4:30 PM ET the same day. A recording of the webcast will be posted on the company’s investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • Benzinga

    The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...

  • ACCESSWIRE

    Viveve Announces Top-line Results of LIBERATE-International Trial for SUI, Q2 Transition to New U.S. Commercial Model, and Pursuit of Financial and Strategic Alternatives

    ENGLEWOOD, CO / ACCESSWIRE / July 22, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today provided an update on the company’s clinical development programs and transition to a new U.S. business model, and also announced that it is conducting a review of financial and strategic alternatives. The company today announced that the LIBERATE-International trial, a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress urinary incontinence (SUI) in women, did not demonstrate greater improvement in SUI in treated patients as compared with the control group, and therefore did not achieve statistical significance in the intent-to-treat-population on the primary endpoint of change from baseline to six months post-treatment in the 1-hour pad weight test.

  • ACCESSWIRE

    Viveve Announces FDA 510(k) Clearance of Viveve 2.0 Next Generation System in the U.S.

    ENGLEWOOD, CO / ACCESSWIRE / June 25, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced 510(k) K190422 clearance by the U.S. Food and Drug Administration (FDA) for the company's next-generation Viveve 2.0 cryogen-cooled monopolar radiofrequency (CMRF) system for use in general surgical procedures for electrocoagulation and hemostasis. "We are pleased to have received 510(k) clearance of the Viveve 2.0 System and its consumable treatment tips from the FDA, which is another important confirmation of the safety profile of our technology.

  • Thomson Reuters StreetEvents

    Edited Transcript of VIVE earnings conference call or presentation 9-May-19 9:00pm GMT

    Q1 2019 Viveve Medical Inc Earnings Call

  • ACCESSWIRE

    Viveve to Present at Raymond James Life Sciences and MedTech Conference

    ENGLEWOOD, CO / ACCESSWIRE / June 11, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Raymond James Life Sciences and MedTech Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • Zacks Small Cap Research

    VIVE: Q1 Results: Restructuring Dramatically Improves Op Loss. $20M Sales Guidance Intact. SUI Data Read-Out This Summer

    By Brian Marckx, CFA READ THE FULL VIVE RESEARCH REPORT    NASDAQ:VIVE Viveve (NASDAQ:VIVE) reported financial results for their fiscal Q1’19 and provided a business update.  Relative to the financials, ...

  • ACCESSWIRE

    Viveve Reports First Quarter 2019 Financial and Operating Results

    - Successful organizational realignment resulting in decreased operating expenses - Significant progress in clinical programs targeting expanded indications in sexual function and stress urinary incontinence ...

  • ACCESSWIRE

    Viveve to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results on May 9, 2019

    ENGLEWOOD, CO / ACCESSWIRE / May 2, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2019 financial and operating results after the close of the U.S. financial markets on Thursday, May 9, 2019, and will host a live conference call and webcast at 5:00 PM ET the same day. A recording of the webcast will be posted on the company's investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • Benzinga

    The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 11) Edap Tms SA (NASDAQ: EDAP ) Down In The Dumps (Biotech ...

  • ACCESSWIRE

    Viveve Announces CE Mark Clearance for its Next Generation 2.0 Platform in the European Union

    ENGLEWOOD, CO / ACCESSWIRE / April 11, 2019 / Viveve Medical Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that the company received CE Mark clearance for its next generation Viveve 2.0 cryogen-cooled monopolar radiofrequency (CMRF) system and tips in the European Union. "As part of our ongoing regulatory strategy to expand the commercial launch of our Viveve 2.0 platform globally, we're extremely pleased that our next generation system and its consumable treatment tips are now available in over 30 countries in Europe.

  • Zacks Small Cap Research

    VIVE: Warning Letter Headwinds Persist, Although Dissipating. 2019 Guidance Implies Much-Improved Operating Loss

    Q4 Results: Warning Letter Headwinds Persist, Although Dissipating. Viveve (VIVE) reported Q4 financial results and provided a business update. While this is down 12% from the prior year, it is about 16% better than what we had anticipated (prior to the preannouncement) and, per management’s comments on the call, reflective of the continued hangover from FDA’s late-July warning letter (which, as a reminder, was not addressed to Viveve but did cause industry-wide disruptions).

  • Thomson Reuters StreetEvents

    Edited Transcript of VIVE earnings conference call or presentation 14-Mar-19 9:00pm GMT

    Q4 2018 Viveve Medical Inc Earnings Call

  • GuruFocus.com

    Viveve Medical Inc (VIVE) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Viveve Medical Inc is a women's sexual health company focused on the commercialization of a non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. Warning! GuruFocus has detected 4 Warning Signs with VIVE.

  • ACCESSWIRE

    Viveve Reports Fourth Quarter and Full Year 2018 Financial Results

    ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the three months ...